MA56534A - Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) - Google Patents
Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)Info
- Publication number
- MA56534A MA56534A MA056534A MA56534A MA56534A MA 56534 A MA56534 A MA 56534A MA 056534 A MA056534 A MA 056534A MA 56534 A MA56534 A MA 56534A MA 56534 A MA56534 A MA 56534A
- Authority
- MA
- Morocco
- Prior art keywords
- hbv
- carbohydrates
- virus
- administration
- vaccines against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863950P | 2019-06-20 | 2019-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56534A true MA56534A (fr) | 2022-04-27 |
Family
ID=71786992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056534A MA56534A (fr) | 2019-06-20 | 2020-06-19 | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220305118A1 (fr) |
EP (1) | EP3986457A1 (fr) |
AU (1) | AU2020297019A1 (fr) |
CA (1) | CA3143627A1 (fr) |
MA (1) | MA56534A (fr) |
WO (1) | WO2020255063A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
US20150010519A1 (en) | 2012-02-09 | 2015-01-08 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
WO2017049291A1 (fr) | 2015-09-18 | 2017-03-23 | Baylor College Of Medicine | Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique |
WO2023094993A1 (fr) * | 2021-11-23 | 2023-06-01 | Baylor College Of Medicine | Lymphocyte t spécifique de virus améliorée |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
JP2001520537A (ja) | 1997-04-03 | 2001-10-30 | エレクトロフェクト・アクティーゼルスカブ | 医薬品と核酸の骨格筋への導入方法 |
US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
KR20010020571A (ko) | 1997-06-30 | 2001-03-15 | 자끄 사비나 | 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션 |
JP2003505114A (ja) | 1998-07-13 | 2003-02-12 | ジェネトロニクス、インコーポレーテッド | パルス電場による皮膚および筋肉を標的とした遺伝子治療 |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
AU2005221687A1 (en) | 2004-03-08 | 2005-09-22 | Ichor Medical Systems, Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
CA2666501C (fr) | 2006-10-17 | 2017-03-21 | Vgx Pharmaceuticals, Inc. | Dispositifs d'electroporation et leurs procedes d'utilisation pour l'electroporation de cellules de mammiferes |
GB0901593D0 (en) | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
GB201502645D0 (en) | 2015-02-17 | 2015-04-01 | Touchlight Genetics Ltd | Method |
KR102535764B1 (ko) | 2016-03-28 | 2023-05-30 | 아이커 메디칼 시스템스 인코포레이티드 | 치료제를 전달하기 위한 장치 |
-
2020
- 2020-06-19 EP EP20746268.0A patent/EP3986457A1/fr active Pending
- 2020-06-19 WO PCT/IB2020/055786 patent/WO2020255063A1/fr active Application Filing
- 2020-06-19 US US17/596,862 patent/US20220305118A1/en active Pending
- 2020-06-19 AU AU2020297019A patent/AU2020297019A1/en not_active Abandoned
- 2020-06-19 MA MA056534A patent/MA56534A/fr unknown
- 2020-06-19 CA CA3143627A patent/CA3143627A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3986457A1 (fr) | 2022-04-27 |
WO2020255063A1 (fr) | 2020-12-24 |
US20220305118A1 (en) | 2022-09-29 |
AU2020297019A1 (en) | 2022-02-17 |
CA3143627A1 (fr) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56534A (fr) | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) | |
MA50278A (fr) | Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb) | |
EP3710049A4 (fr) | Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant les régions pres1 et/ou pres2 et/ou s-hbsag du vhb de la protéine d'enveloppe du vhb | |
EA201692274A1 (ru) | Олигомеры и олигомерные конъюгаты | |
MA51311A (fr) | Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
PH12018500572A1 (en) | Hepatitis b core protein modulators | |
MD20140058A2 (en) | Compositions and methods for treating hepatitis C virus | |
WO2017027350A3 (fr) | Thérapie par interférence arn pour l'infection par le virus de l'hépatite b | |
BR112018009032A8 (pt) | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração | |
MA50520A (fr) | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) | |
MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
NZ628445A (en) | Antiviral compounds with a heterotricycle moiety | |
WO2014179446A3 (fr) | Composés microarn et procédés permettant la modulation de l'activité de mir-122 | |
MY197236A (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
EP3439696A4 (fr) | Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb | |
MA51292A (fr) | Méthodes et appareil pour l'administration de vaccins contre le virus de l'hépatite b (vhb) | |
MA56535A (fr) | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
IL290924A (en) | Vaccines for hepatitis b virus | |
IL287278A (en) | New indole-2-carboxamide compounds active against hepatitis b virus (hbv) | |
MA56524A (fr) | Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
EA201692514A1 (ru) | Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением | |
EP3641772A4 (fr) | Traitement du carcinome hépatocellulaire caractérisé par une infection par le virus de l'hépatite b | |
MX2014014878A (es) | Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv). | |
MA56536A (fr) | Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb) | |
EA201692507A1 (ru) | Фармацевтические комбинации софосбувира и рибавирина |